Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Follicular fluid cerebellin and betatrophin regulate the metabolic functions of growing follicles in polycystic ovary syndrome

  • Ersahin, Aynur Adeviye (Department of Obstetrics and Gynecology, Bahcesehir University School of Medicine) ;
  • Acet, Mustafa (Department of Obstetrics and Gynecology, Medipol University School of Medicine) ;
  • Ersahin, Suat Suphan (Department of Obstetrics and Gynecology, Kemerburgaz University School of Medicine) ;
  • Acet, Tuba (Department of Obstetrics and Gynecology, Medicine Hospital) ;
  • Yardim, Meltem (Department of Medical Biochemistry (Firat Hormones Research Group), Firat University School of Medicine) ;
  • Kenanoglu, Omer (Department of Medical Biochemistry (Firat Hormones Research Group), Firat University School of Medicine) ;
  • Aydin, Suleyman (Department of Medical Biochemistry (Firat Hormones Research Group), Firat University School of Medicine)
  • Received : 2016.04.13
  • Accepted : 2017.02.02
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The aim of this study was to assess the changes of follicular fluid (FF) and serum levels of cerebellin precursor protein 1 (cbln1) and betatrophin in patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. Methods: Twenty infertile women with PCOS and 20 control women diagnosed as poor responders undergoing ovarian stimulation with a GnRH antagonist were included. Blood samples were obtained during ovum pick-up. Follicular fluid from a dominant follicle was collected from the subjects. Using enzyme-linked immunosorbent assays, FF and serum levels of cbln1 and betatrophin were measured in both groups of participants. Metabolic and hormonal parameters were also determined and correlated with each other. Results: Both groups of women had similar serum and FF betatrophin levels ($55.0{\pm}8.9ng/mL$ vs. $53.1{\pm}10.3ng/mL$, p=0.11). The serum and FF betatrophin levels of poor responders were found to be similar ($49.9{\pm}5.9ng/mL$ vs. $48.9{\pm}10.7ng/mL$, p=0.22). Conversely, the FF cbln1 levels of PCOS women were found to be significantly higher than the serum cbln1 levels ($589.1{\pm}147.6ng/L$ vs. $531.7{\pm}74.3ng/L$, p<0.02). The FF cbln1 levels of control participants without PCOS were significantly higher than their serum cbln1 levels ($599.3{\pm}211.5ng/L$ vs. $525.3{\pm}87.0ng/L$, p=0.01). Positive correlations were detected among body mass index, insulin resistance, serum insulin, total testosterone, and betatrophin levels in the PCOS group. Conclusion: Follicular fluid betatrophin and cbln1 concentrations may play a pivotal role on follicular growth in PCOS subjects undergoing IVF/ICSI with an antagonist protocol.

Keywords

References

  1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544-51. https://doi.org/10.1093/humrep/dep399
  2. Celik O, Sahin I, Celik N, Hascalik S, Keskin L, Ozcan H, et al. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Hum Reprod 2007;22:2992-8. https://doi.org/10.1093/humrep/dem286
  3. Fedorcsak P, Storeng R, Dale PO, Tanbo T, Torjesen P, Urbancsek J, et al. Leptin and leptin binding activity in the preovulatory follicle of polycystic ovary syndrome patients. Scand J Clin Lab Invest 2000;60:649-55. https://doi.org/10.1080/00365510050216376
  4. Acet M, Celik N, Acet T, Ilhan S, Yardim M, Aktun HL, et al. Serum and follicular fluid irisin levels in poor and high responder women undergoing IVF/ICSI. Eur Rev Med Pharmacol Sci 2016;20: 1940-6.
  5. Celik O, Aydin S, Celik N, Yilmaz M. Peptides: basic determinants of reproductive functions. Peptides 2015;72:34-43. https://doi.org/10.1016/j.peptides.2015.05.016
  6. Celik O, Celik N, Aydin S, Aygun BK, Haberal ET, Kuloglu T, et al. Ghrelin action on GnRH neurons and pituitary gonadotropes might be mediated by GnIH-GPR147 system. Horm Mol Biol Clin Investig 2016;25:121-8.
  7. Kawwass JF, Summer R, Kallen CB. Direct effects of leptin and adiponectin on peripheral reproductive tissues: a critical review. Mol Hum Reprod 2015;21:617-32. https://doi.org/10.1093/molehr/gav025
  8. Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic ${\beta}$ cell proliferation [retracted in: Cell 2017;168:326]. Cell 2013;153:747-58. https://doi.org/10.1016/j.cell.2013.04.008
  9. Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 2012;424:786-92. https://doi.org/10.1016/j.bbrc.2012.07.038
  10. Zhu JZ, Yu CH, Li YM. Betatrophin provides a new insight into diabetes treatment and lipid metabolism (review). Biomed Rep 2014;2:447-51. https://doi.org/10.3892/br.2014.284
  11. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223-36. https://doi.org/10.1056/NEJMra041536
  12. Calan M, Yilmaz O, Kume T, Unal Kocabas G, Yesil Senses P, Senses YM, et al. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine 2016;53:271-9. https://doi.org/10.1007/s12020-016-0875-z
  13. Espes D, Lau J, Carlsson PO. Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia 2014;57:50-3. https://doi.org/10.1007/s00125-013-3071-1
  14. Chen X, Lu P, He W, Zhang J, Liu L, Yang Y, et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J Clin Endocrinol Metab 2015;100:E96-100. https://doi.org/10.1210/jc.2014-2300
  15. Gomez-Ambrosi J, Pascual E, Catalan V, Rodriguez A, Ramirez B, Silva C, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab 2014;99:E2004-9. https://doi.org/10.1210/jc.2014-1568
  16. Fenzl A, Itariu BK, Kosi L, Fritzer-Szekeres M, Kautzky-Willer A, Stulnig TM, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia 2014;57:1204-8. https://doi.org/10.1007/s00125-014-3208-x
  17. Slemmon JR, Blacher R, Danho W, Hempstead JL, Morgan JI. Isolation and sequencing of two cerebellum-specific peptides. Proc Natl Acad Sci U S A 1984;81:6866-70. https://doi.org/10.1073/pnas.81.21.6866
  18. Satoh F, Takahashi K, Murakami O, Totsune K, Ohneda M, Mizuno Y, et al. Cerebellin and cerebellin mRNA in the human brain, adrenal glands and the tumour tissues of adrenal tumour, ganglioneuroblastoma and neuroblastoma. J Endocrinol 1997;154:27-34. https://doi.org/10.1677/joe.0.1540027
  19. Pang Z, Zuo J, Morgan JI. Cbln3, a novel member of the precerebellin family that binds specifically to Cbln1. J Neurosci 2000;20: 6333-9. https://doi.org/10.1523/JNEUROSCI.20-17-06333.2000
  20. Matsuda K, Miura E, Miyazaki T, Kakegawa W, Emi K, Narumi S, et al. Cbln1 is a ligand for an orphan glutamate receptor delta2, a bidirectional synapse organizer. Science 2010;328:363-8. https://doi.org/10.1126/science.1185152
  21. Mazzocchi G, Andreis PG, De Caro R, Aragona F, Gottardo L, Nussdorfer GG. Cerebellin enhances in vitro secretory activity of human adrenal gland. J Clin Endocrinol Metab 1999;84:632-5. https://doi.org/10.1210/jcem.84.2.5462
  22. Albertin G, Malendowicz LK, Macchi C, Markowska A, Nussdorfer GG. Cerebellin stimulates the secretory activity of the rat adrenal gland: in vitro and in vivo studies. Neuropeptides 2000;34:7-11. https://doi.org/10.1054/npep.1999.0779
  23. Burnet PW, Bretherton-Watt D, Ghatei MA, Bloom SR. Cerebellinlike peptide: tissue distribution in rat and guinea-pig and its release from rat cerebellum, hypothalamus and cerebellar synaptosomes in vitro. Neuroscience 1988;25:605-12. https://doi.org/10.1016/0306-4522(88)90262-X
  24. Strowski MZ, Kaczmarek P, Mergler S, Wiedenmann B, Domin D, Szwajkowski P, et al. Insulinostatic activity of cerebellin: evidence from in vivo and in vitro studies in rats. Regul Pept 2009;157:19-24. https://doi.org/10.1016/j.regpep.2009.05.010
  25. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. https://doi.org/10.1007/BF00280883
  27. Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides 2015;72:4-15. https://doi.org/10.1016/j.peptides.2015.04.012
  28. Crosignani PG, Ragni G, Parazzini F, Wyssling H, Lombroso G, Perotti L. Anthropometric indicators and response to gonadotrophin for ovulation induction. Hum Reprod 1994;9:420-3. https://doi.org/10.1093/oxfordjournals.humrep.a138521
  29. Wass P, Waldenstrom U, Rossner S, Hellberg D. An android body fat distribution in females impairs the pregnancy rate of in-vitro fertilization-embryo transfer. Hum Reprod 1997;12:2057-60. https://doi.org/10.1093/humrep/12.9.2057
  30. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:2606-9. https://doi.org/10.1093/humrep/16.12.2606
  31. Agarwal SK, Vogel K, Weitsman SR, Magoffin DA. Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J Clin Endocrinol Metab 1999;84:1072-6.
  32. Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001; 16:1086-91. https://doi.org/10.1093/humrep/16.6.1086
  33. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001; 75:505-9. https://doi.org/10.1016/S0015-0282(00)01766-0
  34. Celik O, Yesilada E, Hascalik S, Celik N, Sahin I, Keskin L, et al. Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS. Reprod Biomed Online 2010;20:492-8. https://doi.org/10.1016/j.rbmo.2009.12.014
  35. Gonzalez F, Sia CL, Shepard MK, Rote NS, Minium J. Inflammation in response to glucose ingestion is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2012;97:4071-9. https://doi.org/10.1210/jc.2012-2131

Cited by

  1. Navigation problems of ICSI or naive blastocyst can be solved with artificial blastocyst vol.16, pp.None, 2017, https://doi.org/10.1186/s12958-018-0326-1
  2. Circulating Angiopoietin-like 8 protein (ANGPTL8/Betatrophin) in patients with polycystic ovary syndrome: a systematic review and multi effect size meta-analysis vol.35, pp.3, 2017, https://doi.org/10.1080/09513590.2018.1536736